<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00395941</url>
  </required_header>
  <id_info>
    <org_study_id>Pharma 6/699</org_study_id>
    <nct_id>NCT00395941</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Acitretin Plus Pioglitazone in Patients With Psoriasis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Postgraduate Institute of Medical Education and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Postgraduate Institute of Medical Education and Research</source>
  <brief_summary>
    <textblock>
      Acitretin, when given in combiantion with pioglitazone might achieve better and/or more rapid
      control of moderate to severe chronic plaque type psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2006</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in PASI score from baseline in the two groups</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with an improvement of at least 75% in the psoriasis area-and-severity index (PASI) by week 12</measure>
  </secondary_outcome>
  <enrollment>40</enrollment>
  <condition>Psoriasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with chronic plaque type psoriasis having body surface area involvement of &gt;
             20%

          -  Patients of either sex

          -  Females who have completed their family and are tubectomized or are postmenopausal
             i.e. no menstrual bleeding over at least 1 year

          -  Age range 18-65 years

        Exclusion Criteria:

          -  Females of child bearing potential

          -  H/O hypersensitivity to acitretin

          -  Impaired hepatic function (serum bilirubin, AST, ALT and alkaline phosphatase &gt;1.5
             times the upper limit of normal)

          -  Impaired renal function (serum creatinine &gt;1.5mg% in males and &gt;1.4 mg% in females)

          -  Hyperlipidemia

          -  BMI &gt;30 kg /m2

          -  H/O excessive alcohol use

          -  Diabetes mellitus

          -  Congestive heart failure

          -  Ischemic heart disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Sunil Dogra, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Postgraduate Institute of Medical Education and Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samir Malhotra, MD, DM</last_name>
    <phone>+91-172-2755243</phone>
    <email>samirmalhotra345@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PGIMER</name>
      <address>
        <city>Chandigarh</city>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Samir Malhotra, MD, DM</last_name>
      <phone>+91-172-2755243</phone>
      <email>samirmalhotra345@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Promila Pandhi, MD,DM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samir Malhotra, MD, DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Inderjeet Kaur, md</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sunil Dogra, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>November 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2006</study_first_submitted>
  <study_first_submitted_qc>November 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2006</study_first_posted>
  <last_update_submitted>November 3, 2006</last_update_submitted>
  <last_update_submitted_qc>November 3, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2006</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

